Literature DB >> 28769384

MANAGEMENT OF KALA AZAR - AN UPDATE.

S P Kalra1, A Bahl2, Lt Col Pc Sanchetee3, S K Dham4.   

Abstract

Kala azar continues to be a medical problem in India and with the increase in incidence of HIV Infection it is likely that kala azar will be encountered more frequently and in its atypical forms. To aid diagnosis, several immunological tests are now available and they are more sensitive and specific than the aldehyde test. Like many other diseases today, the treatment of kala azar is hampered by drug resistance. Newer drugs are available and so are new delivery systems. Kala azar develops frequently in the HIV infected person before development of AIDS. The presentation is atypical and leishmanial species other than L. donovani may also be the infecting agents. A combination of sandfly control, detection and treatment of patients and prevention of drug resistance continues to the ideal approach for the control of the disease.

Entities:  

Keywords:  HIV; Kala azar; Leishmaniasis

Year:  2017        PMID: 28769384      PMCID: PMC5530401          DOI: 10.1016/S0377-1237(17)30800-6

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  21 in total

1.  Detection of circulating antigen by McAb-AST for evaluating the efficacy of anti-Leishmania chemotherapy.

Authors:  X Hu; F Lin; B Kan; W Yan
Journal:  Chin Med Sci J       Date:  1992-09

2.  Ketoconazole in treatment of visceral leishmaniasis.

Authors:  J P Wali; P Aggarwal; U Gupta; S Saluja; S Singh
Journal:  Lancet       Date:  1990-09-29       Impact factor: 79.321

3.  Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma.

Authors:  R Badaro; E Falcoff; F S Badaro; E M Carvalho; D Pedral-Sampaio; A Barral; J S Carvalho; M Barral-Netto; M Brandely; L Silva
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

4.  Short report: detection of 72-75-kD and 123-kD fractions of Leishmania antigen in urine of patients with visceral leishmaniasis.

Authors:  M De Colmenares; M Portus; C Riera; M Gallego; M J Aisa; S Torras; C Munoz
Journal:  Am J Trop Med Hyg       Date:  1995-05       Impact factor: 2.345

5.  Liposomal amphotericin B in drug-resistant visceral leishmaniasis.

Authors:  R N Davidson; S L Croft; A Scott; M Maini; A H Moody; A D Bryceson
Journal:  Lancet       Date:  1991-05-04       Impact factor: 79.321

6.  Rapid and sensitive detection of Leishmania kinetoplast DNA from spleen and blood samples of kala-azar patients.

Authors:  A J Smyth; A Ghosh; M Q Hassan; D Basu; M H De Bruijn; S Adhya; K K Mallik; D C Barker
Journal:  Parasitology       Date:  1992-10       Impact factor: 3.234

7.  Immunoblotting as a valuable tool to differentiate human visceral leishmaniasis from lymphoproliferative disorders and other clinically similar diseases.

Authors:  A Hoerauf; P P Andrade; C R Andrade; W Solbach; M Röllinghoff
Journal:  Res Immunol       Date:  1992-05

8.  [Visceral leishmaniasis in HIV infection. A totally opportunistic infection].

Authors:  A Cabié; S Matheron; A Leprètre; O Bouchaud; A M Deluol; J P Coulaud
Journal:  Presse Med       Date:  1992-10-24       Impact factor: 1.228

9.  Pentostam (sodium stibogluconate); a 50-year personal reminiscence.

Authors:  L G Goodwin
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 May-Jun       Impact factor: 2.184

10.  Visceral leishmaniasis and HIV-1 co-infection in southern France.

Authors:  E Rosenthal; P Marty; I Poizot-Martin; J Reynes; F Pratlong; A Lafeuillade; D Jaubert; O Boulat; J Dereure; F Gambarelli
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Mar-Apr       Impact factor: 2.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.